GlassScriptPhysician profile
Jack W Erter
NPI 1821145624
$227,851.67
in general payments reported to CMS, 2019-2025
68 companies · $3,002 in 2025
The $3,002 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $29K · 2021: $37K · 2022: $41K · 2023: $49K · 2024: $29K · 2025: $3,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Food and Beverage: $7,681 · Travel and Lodging: $1,116 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,260.00 |
| Food and Beverage | $7,680.53 |
| Travel and Lodging | $1,116.00 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $154,776.21 | 2019-2025 | Calquence, Tagrisso, Imfinzi |
| Genzyme Corporation | $27,102.53 | 2019-2025 | |
| Celgene Corporation | $10,606.84 | 2019-2025 | Reblozyl, Pomalyst |
| Deciphera Pharmaceuticals INC. | $3,933.23 | 2022 | |
| Seagen INC. | $3,374.59 | 2019-2023 | Tukysa, Tivdak |
| Sirtex Medical INC | $3,026.75 | 2019 | |
| Adaptive Biotechnologies Corporation | $2,250.00 | 2020 | |
| Dova Pharmaceuticals | $2,141.03 | 2019-2021 | |
| Adc Therapeutics America, INC. | $2,113.36 | 2021-2025 | |
| Blueprint Medicines Corporation | $2,021.06 | 2020-2025 | Ayvakit |
| Glaxosmithkline, LLC. | $1,989.01 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Janssen Biotech, INC. | $1,894.06 | 2019-2025 | Imbruvica, Darzalex, Talvey |
| Heron Therapeutics, INC. | $1,622.47 | 2019 | |
| Janssen Scientific Affairs, LLC | $1,515.00 | 2022 | |
| Aveo Pharmaceuticals, INC. | $1,447.10 | 2022-2025 | Fotivda |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $749.62 | 2019-2025 | Keytruda, Lynparza |
| Genentech USA, INC. | $514.61 | 2019-2025 | Polivy, Phesgo, Perjeta |
| Novartis Pharmaceuticals Corporation | $483.85 | 2019-2025 | |
| Beigene, LTD. | $450.00 | 2020 | |
| Abbvie INC. | $443.35 | 2022-2025 | |
| Exelixis INC. | $322.56 | 2019-2025 | Cabometyx |
| Daiichi Sankyo INC. | $318.99 | 2019-2025 | Enhertu |
| Eisai INC. | $292.92 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $254.40 | 2019-2025 | Iclusig, Fruzaqla, Alunbrig |
| E.R. Squibb & Sons, L.L.C. | $244.96 | 2019-2025 | Opdivo |
| Genmab U.S., INC. | $232.25 | 2023-2024 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $204.90 | 2019-2025 | |
| Pfizer INC. | $203.76 | 2019-2025 | |
| Gilead Sciences, INC. | $203.54 | 2019-2025 | Trodelvy |
| Incyte Corporation | $180.86 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Kite Pharma, INC. | $180.31 | 2020-2025 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $172.35 | 2022-2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $170.89 | 2023-2024 | Zepzelca |
| Astellas Pharma US INC | $167.58 | 2019-2025 | Xtandi, Xospata, Vyloy |
| Syndax Pharmaceuticals, INC. | $159.18 | 2025 | Revuforj |
| Ethicon US, LLC | $156.38 | 2023 | Certus 140 |
| Novocure INC. | $147.66 | 2019 | |
| Beone Medicines USA, INC. | $120.78 | 2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $117.50 | 2022-2024 | Xpovio |
| Amgen INC. | $114.26 | 2019-2023 | Kyprolis |
| Beigene USA, INC. | $112.46 | 2022-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $92.91 | 2019-2023 | Imbruvica |
| Taiho Oncology, INC. | $84.83 | 2019-2025 | |
| Legend Biotech USA INC. | $78.85 | 2025 | Carvykti |
| Alexion Pharmaceuticals, INC. | $78.72 | 2023-2025 | Ultomiris |
| Mirati Therapeutics, INC. | $70.28 | 2023 | Krazati |
| Puma Biotechnology, INC. | $65.88 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $59.63 | 2024-2025 | Monoferric, Cosela |
| Sun Pharmaceutical Industries INC. | $57.65 | 2024-2025 | |
| Tersera Therapeutics LLC | $55.89 | 2023-2025 | Xermelo, Zoladex |
| Rigel Pharmaceuticals, INC. | $53.60 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Agios Pharmaceuticals, INC. | $52.53 | 2025 | Pyrukynd |
| Geron Corporation | $51.71 | 2025 | Rytelo |
| Teva Pharmaceuticals USA, INC. | $48.05 | 2019 | |
| Lilly USA, LLC | $46.93 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmaessentia USA Corporation | $46.85 | 2024-2025 | Besremi |
| Array Biopharma INC | $46.45 | 2024 | Braftovi, Mektovi, Xalkori |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.44 | 2019-2025 | Gilotrif |
| Servier Pharmaceuticals LLC | $44.52 | 2024-2025 | |
| Cti Biopharma Corp. | $37.21 | 2023 | Vonjo |
| Tesaro, INC. | $35.63 | 2019 | |
| Emd Serono, INC. | $32.16 | 2019-2023 | Bavencio |
| Sobi, INC | $25.93 | 2023 | |
| Iovance Biotherapeutics, INC. | $24.54 | 2025 | Amtagvi |
| Ipsen Biopharmaceuticals, INC | $22.66 | 2024 | Onivyde |
| Lexicon Pharmaceuticals, INC. | $21.98 | 2019 | |
| Biocompatibles, INC. | $18.99 | 2019 | |
| Mylan Institutional INC. | $18.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Erter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.